country

Change Language

EN - English
FR - Français
DE - Deutsch
ES - Español
JA - 日本語
KO - 한국어

Country or Region:

United States

Product Name	Size / Unit Price	Qty

Total: USD 0.00 Checkout

Cat. No.: HY-181082

Copy Link Print Information

Aurora kinase-IN-10

Aurora kinase-IN-10 is an Aurora kinase inhibitor. Aurora kinase-IN-10 exhibits IC₅₀ values of 5.94 nM and 86.06 nM against Aurora A and Aurora B, respectively. Aurora kinase-IN-10 has anti-tumor activity and can be used in the research of tumors such as triple-negative breast cancer.

For research use only. We do not sell to patients.

CAS No.: 3053885-69-8
Formula: C₂₆H₂₆FN₇O
Molecular Weight:471.53

Storage:

Please store the product under the recommended conditions in the Certificate of Analysis.

Data Sheet (270 KB)

Aurora kinase-IN-10 Chemical Structure

CAS No.: 3053885-69-8

Price

Stock

Quantity

Amount: USD 0.00

* Please select Quantity before adding items.

Use of MCE Products

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biological Activity
- Description
- IC₅₀ & Target
- In Vitro
- Parmacokinetics
- In Vivo
Chemical Information
Protocols (2)
Purity & Documentation
References
Calculators
Help & FAQs
Classifications
Bioz

Biological Activity

Description

IC₅₀ & Target

^[1]

Aurora A

5.94 nM (IC₅₀)

Aurora B

86.06 nM (IC₅₀)

All Aurora Kinase Isoforms :

In Vitro

Aurora kinase-IN-10 (48 h) inhibits the proliferation of MDA-MB-231, A549, PC9 and LO2 cells, with IC₅₀ values of 1.49, 19.44, 6.57 and 48.11 μM, respectively^[1].
Aurora kinase-IN-10 has a half-life of 126.6 min in rat liver microsomes and approximately 18.3 h in rat plasma^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.

Parmacokinetics

Species	Dose	Route	C_max	AUC_0-t	AUC_0-∞	V_z	T_1/2	CL	MRT_0-t	F
Rat^[1]	5 mg/kg	i.v.	3427.29 ng/mL	6674.48 ng·h/mL	6751.40 ng·h/mL	69.84 L/kg	4.15 h	639.92 mL/h/kg	6.55 h	/
Rat^[1]	10 mg/kg	p.o.	7511.55 ng/mL	6742.80 ng·h/mL	7832.47 ng·h/mL	177.37 L/kg	5.57 h	1184.17 mL/h/kg	7.18 h	58 %

In Vivo

Aurora kinase-IN-10 (Compound 4q) (15 mg/kg; i.p.; once every 2 days; 20 days) exhibits potent in vivo anti-tumor efficacy in the MDA-MB-231 xenograft mouse model^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

BALB/c nude mice (female, 4-5 weeks old, 19-22 g, MDA-MB-231 xenograft model)^[1]
Dosage:

15 mg/kg
Administration:

i.p.; every two days; 20 consecutive days
Result:

Achieved a tumor growth inhibition rate of 56.7%.
Showed no significant body weight change compared to the vehicle group.
Produced no significant histopathological alterations in major organs (heart, liver, spleen, lung, kidney) on hematoxylin-eosin staining.

Chemical Information

CAS No. 3053885-69-8
Molecular Weight 471.53
Formula C₂₆H₂₆FN₇O
SMILES

CC(N1CCN(CC1)C2=CC=C3C(N=C(N=C3NC4=NNC(C)=C4)/C=C/C5=CC=C(C=C5)F)=C2)=O
Shipping

Room temperature in continental US; may vary elsewhere.
Storage

Please store the product under the recommended conditions in the Certificate of Analysis.

Protocols

All Cell Biology Animals and Diseases

Cell Cytotoxicity Assay
Cytotoxicity assays are usually based on the assessment of cell membrane damage, which can also be indirectly detected by measuring cell viability. Detection methods include MTT assay, CKK-8 assay, LDH assay and ATP assay, etc.
Breast Cancer Modeling
Breast cancer is a heterogeneous cancer, and it has been distinguished into four subtypes: luminal A, luminal B, HER2-positive and basal-like. Molecular mutations, epigenetic alterations, hormone exposure and immune microenvironment are related to the progression of breast cancer.

Purity & Documentation

Select Batch:

Purity: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (270 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

References

[1]. Chen S, et al. Computer-Aided optimization of quinazoline-based Aurora kinase inhibitors for enhanced metabolic stability. Eur J Med Chem. 2026;305:118548. [Content Brief]

Calculators

Molarity Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Concentration Concentration

Volume Volume

Molecular Weight Molecular Weight

Dilution Calculator

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start) Concentration _(start)

Volume _(start) Volume _(start)

Concentration _(final) Concentration _(final)

Volume _(final) Volume _(final)

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Bioz

Keywords

MOQ

Minimum order quantity

100 mg

Get Quote In-stock

Other size

Get Quote